Skip to content

Study · Animal study (in vivo) · mouse · 2015

4 results

Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.

Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I

Scientific reports10 Nov 2015Cited by 29 (Europe PMC)

PMID26553741 (opens in a new tab)PMCIDPMC4639790 (opens in a new tab)DOI10.1038/srep16300 (opens in a new tab)PepBankPUB-26553741
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Mutated disrupted in schizophrenia 1 (DISC1), a microtubule regulating protein, leads to schizophrenia and other psychiatric illnesses. It is hypothesized that microtubule stabilization may provide neuroprotection in schizophrenia. The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection. Bioinformatics prediction for FDA approved drugs mimicking SxIP-like motif which displace NAP-EB binding identified Risperidone. Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model. NAP but not Risperidone, reduced anxiety in the mutated mice. Doxycycline, which blocked the expression of the mutated DISC1, did not reverse the phenotype. Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both. Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mutated DISC1 mice, NAP ameliorated object recognition deficits.

    In plain wordsIn mice with mutated DISC1, NAP reduced object recognition deficits.

    Peptide
    Davunetide
    Outcome
    DecreaseObject recognition deficits
    Study

    mousen: not reported in source

    mutated DISC1 mouse model
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mutated DISC1 mice, NAP reduced anxiety, whereas Risperidone did not.

    In plain wordsIn mice with mutated DISC1, NAP reduced anxiety, whereas Risperidone did not.

    Peptide
    Davunetide
    Outcome
    DecreaseAnxiety
    Study

    mousen: not reported in source

    mutated DISC1 mouse model
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP but not Risperidone, reduced anxiety in the mutated mice.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mutated DISC1 mice, NAP significantly lowered hippocampal Foxp2 transcripts.

    In plain wordsIn mice with mutated DISC1, NAP lowered hippocampal Foxp2 transcripts.

    Peptide
    Davunetide
    Outcome
    DecreaseHippocampal Foxp2 transcripts
    Study

    mousen: not reported in source

    mutated DISC1 mouse model
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both.

Studies that did not test the peptide alone1

In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Davunetide.

  1. 04AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism

    In mutated DISC1 mice, combined NAP and Risperidone significantly lowered hippocampal Foxp2 transcripts.

    In plain wordsIn mice with mutated DISC1, combined NAP and Risperidone lowered hippocampal Foxp2 transcripts.

    Peptide
    Davunetide
    Outcome
    DecreaseHippocampal Foxp2 transcripts with combination treatment
    Study

    mousen: not reported in source

    mutated DISC1 mouse model
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.